Sangamo Biosciences reported $554.06M in Current Assets for its second fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Current Assets Change
Acceleron Pharma XLRN:US $ 717.77M 19.84M
Alnylam Pharmaceuticals ALNY:US $ 2725.16M 255.08M
Amgen AMGN:US $ 19099M 2200M
Avrobio Inc AVRO:US 233.52M 8.54M
Bayer BAYN:GR 32.45B 3.35B
Biogen BIIB:US $ 7183.7M 464.2M
Biomarin Pharmaceutical BMRN:US $ 2357.84M 69.07M
Bluebird Bio BLUE:US $ 903.53M 194.01M
Gilead Sciences GILD:US $ 14498M 1220M
GlaxoSmithKline GSK:LN 17.57B 958M
Intercept Pharmaceuticals ICPT:US $ 493.1M 5.54M
IONIS PHARMACEUT IONS:US $ 2238.42M 249M
Karyopharm Therapeutics KPTI:US $ 273.5M 17.99M
Novartis NOVN:VX 23.81B 1.61B
Omeros OMER:US $ 112.4M 20.08M
Regulus Therapeutics RGLS:US $ 46.31M 9.78M
Sangamo Biosciences SGMO:US $ 554.06M 52.88M
Sarepta Therapeutics SRPT:US $ 2265.22M 6.13M
Ultragenyx Pharmaceutical RARE:US $ 949.49M 121.44M
Vertex Pharmaceuticals VRTX:US $ 8457.51M 81.79M
Ziopharm Oncology ZIOP:US $ 89.41M 23.3M